Track topics on Twitter Track topics that are important to you
The designation has been granted for Pomalyst to treat patients with HIV-positive Kaposi sarcoma who have previously received systemic chemotherapy, in addition to patients with HIV‐negative Kaposi’s sarcoma.
The post Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma appeared first on Pharmaceutical Business review.NEXT ARTICLE
Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...